ReviewAdvances in experimental medicine and biology2017
Roles of RUNX in Hippo Pathway Signaling.
Review in Advances in experimental medicine and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- YAP/TAZ: An epitome of tumorigenesis.Cancer letters · 2025Review
- Transient activation of YAP/TAZ confers resistance to morusin-induced apoptosis.BMC molecular and cell biology · 2025Article
- Radiation-induced YAP/TEAD4 binding confers non-small cell lung cancer radioresistance via promoting NRP1 transcription.Cell death & disease · 2024Article
- Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.Cell death and differentiation · 2023Article
- Review
- A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation.Cell reports · 2022Article
- USP26 promotes anaplastic thyroid cancer progression by stabilizing TAZ.Cell death & disease · 2022Article
- Circulating Long Non-Coding RNAs LINC00324 and LOC100507053 as Potential Liquid Biopsy Markers for Esophageal Squamous Cell Carcinoma: A Pilot Study.Frontiers in oncology · 2022Article
- Review
- MINDY1 promotes bladder cancer progression by stabilizing YAP.Cancer cell international · 2021Article
- Review
- Identification of Components of the Hippo Pathway inFrontiers in genetics · 2021Article
- RACO-1 modulates Hippo signalling in oesophageal squamous cell carcinoma.Journal of cellular and molecular medicine · 2020Article
- Review
- Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression.Nature cell biology · 2020Article
- Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.Cell reports · 2020Article
- Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.Theranostics · 2020Article
- NUSAP1 Promotes Gastric Cancer Tumorigenesis and Progression by Stabilizing the YAP1 Protein.Frontiers in oncology · 2020Article
- Expression pattern of YAP and TAZ during orthodontic tooth movement in rats.Journal of molecular histology · 2018Article
- Alternative Splicing in the Hippo Pathway-Implications for Disease and Potential Therapeutic Targets.Genes · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The Runt-domain (RD) transcription factors (RUNX genes) are an important family of transcriptional mediators that interact with a variety of proteins including the Hippo pathway effector proteins, YAP and TAZ. In this chapter we focus on two examples of RUNX-TAZ/YAP interactions that have particular significance in human cancer. Specifically, recent evidence has found that RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition mediated by the soluble N-terminal ectodomain of E-Cadherin, sE-Cad. Contrastingly, in gastric cancer, RUNX3 acts as a tumor suppressor via inhibition of the YAP-TEAD complex and disruption of downstream YAP-mediated gene transcription and the oncogenic phenotype. The reports highlighted in this chapter add to the growing repertoire of instances of Hippo pathway crosstalk that have been identified in cancer. Elucidation of these increasingly complex interactions may help to identify novel strategies to target Hippo pathway dysregulation in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.